Veradermics, Incorporated
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the de… Read more
Veradermics, Incorporated (MANE) - Total Liabilities
Latest total liabilities as of September 2025: $114.81 Million USD
Based on the latest financial reports, Veradermics, Incorporated (MANE) has total liabilities worth $114.81 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Veradermics, Incorporated - Total Liabilities Trend (2023–2024)
This chart illustrates how Veradermics, Incorporated's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Veradermics, Incorporated Competitors by Total Liabilities
The table below lists competitors of Veradermics, Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rockworth Public Company Limited
BK:ROCK
|
Thailand | ฿443.11 Million |
|
MOELIS & COMPANY (A)
BE:17M
|
Germany | €666.38 Million |
|
Toys"R"Us ANZ Limited
PINK:TOYRF
|
USA | $23.38 Million |
|
STNLY BLCK&DECK
BE:SWF
|
Germany | €13.62 Billion |
|
FINMECCANICA - Dusseldorf Stock Exchang
DU:FMNB
|
Germany | €22.13 Billion |
|
E79 Resources Corp
OTCQB:ESVNF
|
USA | $13.38K |
|
Earthwise Minerals Corp.
F:966
|
Germany | €1.12 Million |
Liability Composition Analysis (2023–2024)
This chart breaks down Veradermics, Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Veradermics, Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Veradermics, Incorporated (2023–2024)
The table below shows the annual total liabilities of Veradermics, Incorporated from 2023 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.72 Million | +22.93% |
| 2023-12-31 | $3.84 Million | -- |